Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer
AbstractNeoadjuvant cisplatin‐based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle‐invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (
Source: The Oncologist - Category: Cancer & Oncology Authors: Chelsea K. Osterman, Dilip S. Babu, Daniel M. Geynisman, Bianca Lewis, Robert A. Somer, Arjun V. Balar, Matthew R. Zibelman, Elizabeth A. Guancial, Gianna Antinori, Shun Yu, Vivek Narayan, Thomas J. Guzzo, Elizabeth R. Plimack, David J. Vaughn, Chunkit Fu Tags: Genitourinary Cancer Brief Communications Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy